MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$130,875K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from sale of series a c...
Sales and maturities of marketab...
Stock-based compensation expense
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Payment of issuance costs
Prepaid expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2025-12-31
2025-06-30
Net loss
-24,603
-51,038
-
Accretion of discount on marketable securities
157
389
-
Non-cash operating lease expense
78
151
-
Stock-based compensation expense
5,530
6,449
-
Write-off of deferred financing costs
-
230
-
Prepaid expenses and other current assets
826
1,830
-
Accounts payable, accrued expenses and other current liabilities
401
929
-
Operating lease liabilities
-78
-152
-
Other assets
55
-
-
Net cash used in operating activities
-19,710
-45,650
-
Purchases of marketable securities
46,647
106,864
-
Sales and maturities of marketable securities
32,843
111,420
-
Net cash provided by investing activities
-13,804
4,556
-
Proceeds from sale of series a common stock
175,000
0
-
Payment of issuance costs
10,800
0
-
Proceeds from exercise of stock options
96
275
-
Proceeds from purchases under employee stock purchase plan
93
-
-
Net cash provided by financing activities
164,389
275
-
Net (decrease) increase in cash and cash equivalents
130,875
-7,306
-33,513
Cash and cash equivalents at beginning of period
35,021
75,840
-
Cash and cash equivalents at end of period
165,896
35,021
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from sale of
series a common stock
$175,000K
Proceeds from exercise of
stock options
$96K
Proceeds from purchases
under employee stock...
$93K
Net cash provided by
financing activities
$164,389K
Canceled cashflow
$10,800K
Net (decrease)
increase in cash and cash...
$130,875K
(490.52%↑ Y/Y)
Canceled cashflow
$33,514K
Payment of issuance
costs
$10,800K
Stock-based compensation
expense
$5,530K
Accounts payable,
accrued expenses and...
$401K
Non-cash operating lease
expense
$78K
Sales and maturities
of marketable...
$32,843K
Net cash used in
operating activities
-$19,710K
Net cash provided by
investing activities
-$13,804K
Canceled cashflow
$6,009K
Canceled cashflow
$32,843K
Net loss
-$24,603K
Purchases of marketable
securities
$46,647K
Prepaid expenses and
other current assets
$826K
Accretion of discount on
marketable securities
$157K
Operating lease
liabilities
-$78K
Other assets
$55K
Buy us a coffee
Sagimet Biosciences Inc. (SGMT)
Sagimet Biosciences Inc. (SGMT)